Evan Wang
Stock Analyst at Guggenheim
(n/a)
# 4,905
Out of 4,941 analysts
5
Total ratings
n/a
Success rate
-44.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Maintains: Buy | $56 → $62 | $30.88 | +100.78% | 1 | Jun 10, 2025 | |
| CVAC CureVac | Reiterates: Neutral | n/a | $5.47 | - | 1 | Apr 5, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $0.78 | +1,053.40% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $9.40 | +80.85% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $25.66 | - | 1 | Apr 26, 2023 |
Metsera
Jun 10, 2025
Maintains: Buy
Price Target: $56 → $62
Current: $30.88
Upside: +100.78%
CureVac
Apr 5, 2024
Reiterates: Neutral
Price Target: n/a
Current: $5.47
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $0.78
Upside: +1,053.40%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $9.40
Upside: +80.85%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $25.66
Upside: -